Modulation of inflammatory response after myocardial infarction: one explanation for the cardiovascular benefit of empagliflozin in the EMMY trial?

Antonin Trimaille^{1

2}, Benjamin Marchandot¹, Olivier Morel^{1

2}

Affiliations

¹ Department of Cardiovascular Medicine, Nouvel Hôpital Civil, Strasbourg University Hospital, 1 place de l'Hôpital, 67000 Strasbourg, Grand-Est, France.
² INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, FMTS, 1 Rue Eugene Boeckel, 67000 Strasbourg, Grand-Est, France.

Antonin Trimaille et al. Eur Heart J. 2023.

. 2023 Oct 12;44(38):3929-3930.

doi: 10.1093/eurheartj/ehad257.

Antonin Trimaille^{1

2}, Benjamin Marchandot¹, Olivier Morel^{1

2}

¹ Department of Cardiovascular Medicine, Nouvel Hôpital Civil, Strasbourg University Hospital, 1 place de l'Hôpital, 67000 Strasbourg, Grand-Est, France.
² INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, FMTS, 1 Rue Eugene Boeckel, 67000 Strasbourg, Grand-Est, France.

No abstract available

Comment in

SGLT2 inhibition could potentially impact inflammation in acute myocardial infarction.
Sourij H, Aziz F, Mangge H, von Lewinski D. Sourij H, et al. Eur Heart J. 2023 Oct 12;44(38):3931. doi: 10.1093/eurheartj/ehad404. Eur Heart J. 2023. PMID: 37350395 No abstract available.